ImmuPharma plc (LON:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announced today that the Company’s Annual General Meeting confirmed for Thursday, 18 June 2020 @ 10.30am, will now be held at: 52 Grosvenor Garden, London SW1W 0AU.
The COVID-19 Guidance rules still apply, as set out in the announcement issued on 21 May 2020, (see below). Any shareholders attempting to gain access to the AGM will be excluded from the meeting on the ground of public safety.
We note the current issues surrounding COVID-19 (coronavirus) and the rapidly developing public health guidance in the UK at the time of writing. This includes the stringent requirements announced on 23 March 2020, which require UK nationals to stay at home except in tightly defined circumstances (which do not include attending an AGM), the social distancing and shielding guidance for those over the age of 70 or with underlying medical conditions, and the ban on all non-essential travel. The health and safety of our shareholders and colleagues is always our utmost priority.
As it is no longer possible to hold the AGM in the way that the ImmuPharma Board had planned, we cannot allow shareholders to attend in person. Any shareholders attempting to gain access to the AGM will be excluded from the meeting on grounds of public safety. In the light of the above, we strongly encourage you to consider ensuring your vote is counted by submission of the proxy by post as detailed in the Notice of Annual General Meeting.
